Theriva Biologics, Inc. filed a Form 8-K on November 2, 2026, disclosing that on October 30, 2026, the company entered into and simultaneously closed an Asset Purchase and Sale Agreement with Biossil Labs Inc. covering its SYN-004 (ribaxamase) and SYN-006 (carbapenemase) product candidates.

Key Highlights

  • Upfront payment: Biossil paid Theriva Biologics $350,000 at closing, described as non-refundable and non-creditable against other amounts payable under the Purchase Agreement.
  • Potential milestone payments: The company is eligible for up to $3 million in regulatory milestones and up to $88 million in sales milestones, each payable only once regardless of the number of products or indications.
  • Running royalty: Theriva may receive a low-single-digit percentage royalty on worldwide net sales, subject to a cap of $250 million.
  • License consideration share: Theriva is entitled to a low-double-digit percentage of certain license consideration received by Biossil, not subject to the royalty cap.
  • PREV Amendment payment: Concurrent with the closing, Theriva paid PREV ABR LLC $140,000, with future obligations to share 50% of regulatory and sales milestones, 33-1/3% of royalties, and 50% of other consideration, subject to an aggregate cap of $13.0 million.
  • Transition assistance: Theriva agreed to provide transition assistance to Biossil for 120 days following the closing.

Theriva Biologics Transfers Ribaxamase and Carbapenemase Assets to Canadian Buyer

According to the filing, Theriva Biologics (NYSE American:TOVX) executed and simultaneously closed an Asset Purchase and Sale Agreement with Biossil Labs Inc., a Canadian corporation, on October 30, 2026. The purchased assets include patents and other intellectual property exclusively related to SYN-004 (ribaxamase, including improvements and SYN-007) and certain assets exclusively related to SYN-006, the company's carbapenemase product candidate. The filing states the transferred assets also encompass specified contracts, regulatory filings and approvals including an investigational new drug application, existing inventory and materials, books, records and data, and related claims and rights of recovery.

The filing discloses that Biossil assumed only liabilities arising after the closing from its ownership or exploitation of the purchased assets and post-closing obligations under assumed contracts. Theriva retained all other liabilities, including those arising from its pre-closing ownership or exploitation of the purchased assets. At closing, Theriva also granted Biossil a non-exclusive, perpetual, irrevocable, worldwide, fully paid-up, royalty-free license under certain company intellectual property not included in the purchased assets, solely to the extent necessary to exploit the products. The filing states that Biossil has sole control over development and commercialization and has agreed to use commercially reasonable efforts to develop and obtain regulatory approval for at least one product.

The filing also discloses a concurrent amendment to a prior agreement with PREV ABR LLC, originally dated November 7, 2012, when the company was known as Synthetic Biologics, Inc. Pursuant to the PREV Amendment, Theriva paid PREV $140,000 at closing and will owe PREV specified percentages of future receipts from Biossil, subject to an aggregate cap of $13.0 million inclusive of the $140,000 closing payment. The filing includes the explicit caution that "there can be no assurance that any milestone will be achieved, that any product will be approved or commercialized, or that the Company will receive any payments beyond the upfront payment."

What Was Disclosed

Theriva Biologics disclosed the closing of a sale of its ribaxamase and carbapenemase-related assets to Biossil Labs Inc. for $350,000 upfront, with potential milestone, royalty, and license-consideration payments, alongside a concurrent amendment to an existing agreement with PREV ABR LLC establishing revenue-sharing obligations subject to a $13.0 million aggregate cap.